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A B S T R A C T
Objectives: Discordance between frozen section diagnosis and the deﬁnite histopathological diagnosis and the
fact that the frozen section result is not always unambiguous, may contribute to diﬀerences in clinical practice
regarding perioperative treatment and follow-up of borderline ovarian tumours (BOTs) patients amongst gy-
naecologic oncologists, which may lead to over- and undertreatment. The aim of the study was to map the Dutch
gynaecologists' preferred treatment and follow-up strategy in case of BOTs.
Methods: A questionnaire was sent to all Dutch gynaecologists involved in ovarian surgery with perioperative
frozen section analysis, and the outcomes were assessed using descriptive statistics.
Results: Nearly half of the respondents (41.0%) would not perform a staging procedure in case of a BOT. In case
of an ambiguous frozen section diagnosis, tending towards invasive carcinoma, a considerable number (sBOT
56.4%; mBOT 30.8%) would perform a lymph node sampling as part of the staging procedure. A relaparotomy/
relaparoscopy, to perform a lymph node sampling in case of a serous or mucinous carcinoma after a BOT frozen
section diagnosis, would be performed by 97.4% and 48.7% of the respondents, respectively.
Conclusions: A considerable number of gynaecologists would perform a staging procedure that is recommended
for ovarian cancer in case of an ambiguous BOT frozen section diagnosis, especially for serous tumours. In
addition, nearly all gynaecologists would perform a second procedure including a lymph node sampling in case
of a serous invasive carcinoma after a BOT frozen section diagnosis, which applies to half of the gynaecologists in
case of a mucinous carcinoma.
1. Introduction
In contrast to most other organs, the classiﬁcation of surface epi-
thelial tumours of the ovary (including serous and mucinous tumours)
does not only include benign and malignant tumours, but also an in-
termediate category of so-called borderline tumours. From a patholo-
gical and etiological point of view, serous and mucinous borderline
tumours are completely diﬀerent, resulting in major diﬀerences in their
biological behaviour (Kurman and International Agency for Research
on Cancer, 2014). From a clinical point of view, intraoperative decision
making is mainly dependent on the pathologists' judgment regarding
the frozen section analysis: benign, borderline, or malignant, con-
sidering the histological appearance of the tumour as less important at
that timepoint. For this reason, some gynaecologists pragmatically
group mucinous and serous borderline tumours together. Since the
biological behaviour of borderline ovarian tumours is diﬃcult to pre-
dict, optimal intraoperative management, with respect to frozen section
analysis, followed by abdominal staging, remains a matter of debate.
According to Dutch guidelines, a surgical staging procedure is re-
commended when a Borderline Ovarian Tumour (BOT) is diagnosed
during an exploratory laparotomy with frozen section analysis
(Werkgroep Oncologische Gynaecologie (WOG), n.d.). Such a staging
procedure includes, in addition to taking abdominal (rinsing) ﬂuid for
cytology and resection of at least the pathological adnex, a thorough
inspection and palpation of the abdominal cavity, intestines and me-
sentery, omentum, and assessment of the contralateral ovary. Evident
deviant areas must be excised. An infracolic omentectomy and collec-
tion of standardized peritoneal biopsies (from both paracolic gutters,
the right diaphragmatic dome, the bladder dome and pouch of Douglas)
is considered useful for ﬁnding peritoneal implants and determining the
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deﬁnite stage and related prognosis, but has no consequences for the
treatment (Morice et al., 2003; Trope et al., 1993; Akeson et al., 2008;
De Decker et al., 2017). Furthermore, an appendectomy is advised in
case of a mucinous BOT (mBOT) (Hart, 2005; Sherman et al., 2004).
When a BOT diagnosis is established postoperatively, a relaparotomy is
not indicated (Fauvet et al., 2004; Camatte et al., 2004). Follow-up in
case of BOTs is advised only for patients with a remaining ovary and
patients with a serous BOT (sBOT) with invasive peritoneal implants,
which are also designated as extra-ovarian low-grade serous carcinoma
(LGSC) (Kurman and International Agency for Research on Cancer,
2014; Yokoyama et al., 2006; Morice et al., 2012).
There are diﬀerences in clinical practice regarding perioperative
treatment and follow-up of BOT patients amongst gynaecologic oncol-
ogists. Besides some optional parts of the staging procedure, another
important diﬀerence in the treatment of BOTs amongst gynaecologic
oncologists may be related to a discordance between the BOT frozen
section diagnosis and a deﬁnite histopathological diagnosis of invasive
ovarian cancer (10–17% of the patients) (Pongsuvareeyakul et al.,
2012; Bozdag et al., 2016; Ayhan et al., 2016). Some gynaecologists
advocate a staging procedure as is recommended in case of invasive
ovarian carcinoma, with the risk of overtreatment, whereas others will
await the deﬁnitive pathological diagnosis, which may necessitate a
second surgical procedure to complete the staging procedure. Finally,
the perioperative histopathological BOT diagnoses based on frozen
section analyses may be not unambiguous (e.g., “borderline tumour of
the ovary, but cannot exclude invasive cancer”, “minimum borderline
tumour of the ovary” or “borderline ovarian tumour and strong suspi-
cion of invasive disease”), which is partly due to the common and well-
known problem of sampling error in BOTs. It is interesting to know
whether a gynaecologic oncologist will perform a second procedure in
cases of invasive cancer as the ﬁnal pathological result to complete
staging irrespective of histological subtype. Recently, it has been shown
that the chance of positive lymph nodes in case of mucinous ovarian
carcinomas is rare, making it questionable whether lymph node staging
is really necessary (Kleppe et al., 2011; Moroney et al., 2018; Nasioudis
et al., 2017).
The aforementioned aspects may lead to diﬀerent treatment and
follow-up policies, which may ultimately lead to overtreatment because
of unnecessary lymph node sampling and temporary undertreatment
because of lack of lymph node sampling, necessitating a second pro-
cedure. To improve this, it is important to have more detailed in-
formation about current clinical practice regarding treatment and
follow-up strategies of gynaecologic oncologists dealing with BOTs. The
aim of the present study was to map the gynaecologists' preferred
treatment and follow-up strategy in The Netherlands, with a special
interest in the preferred staging procedure in case of both ambiguous
and unambiguous BOT frozen section diagnoses, how they deal with
patients with a deﬁnitive diagnosis of invasive carcinoma and initial
staging according to the BOT frozen section diagnosis and whether
there are diﬀerences between serous and mucinous tumours regarding
these situations.
2. Methods
An anonymous electronic web-based questionnaire was developed
according to the Checklist for Reporting Results of Internet E-Surveys
(CHERRIES) guidelines (see supplementary material 1 for a completed
checklist) (Eysenbach, 2004). Approval of the Ethics Review Committee
was unnecessary because all items of the questionnaire were based on
ﬁctitious cases and because this was a study amongst physicians.
The questionnaire was intended for gynaecologists who perform
debulking surgery and/or staging procedures with respect to ovarian
tumours. Dutch hospitals are classiﬁed according to their level of spe-
cialization as general, semi-specialized, or specialized hospitals (in-
cluding all University hospitals). Since 2012, surgical care for ovarian
cancer is centralized in the Netherlands, and staging and debulking
surgery is solely executed in hospitals that perform a minimum of 20
debulking surgeries annually. These are semi-specialized or specialized
hospitals, and the distinction between the two types of hospitals is
deﬁned by the employment of gynaecological oncologists. Following a
two-year fellowship in gynaecologic oncology, the Dutch Society of
Gynaecologic Oncology can certify members as gynaecological oncol-
ogists. In semi-specialized hospitals, gynaecological oncologists parti-
cipate in each debulking surgery together with semi-specialized gy-
naecologists. In order to reach out to gynaecologists who perform
staging procedures, the questionnaire was sent by email to all gynae-
cologists who are a member of the Working Party on Oncologic
Gynaecology, which is part of the Dutch Association of Obstetrics and
Gynaecology (http://www.nvog.nl) (n=251).
Of these 251 gynaecologists, 59 are a gynaecologic oncologist and
10 are gynaecologic oncologist in training. The remainder are semi-
specialized or general gynaecologists, the latter being gynaecologists
with an interest in gynaecological oncology, but who do not ﬁt in any of
the foregoing professional proﬁles.
All authors were involved in compiling and testing the ques-
tionnaire, which consisted of a maximum of 27 items (see supplemen-
tary material 2) concerning staging procedures in case of BOTs. It was
taken into account that a considerable number of possible respondents
do not perform ovarian surgery with frozen section analysis, but might
have done so in the past. In those cases, the questionnaire was com-
pleted after the 4th question. The ﬁrst part consisted of general ques-
tions (e.g., the gynaecologist's gender, professional function), the
second and third part were aimed at the surgical strategy in case of
sBOTs or mBOTs, respectively. The last two parts of the survey involved
questions with respect to the follow-up of sBOTs and mBOTs, respec-
tively. All questions were multiple choice, and it was possible to specify
the answer for some questions.
Invitation emails with a personal link to start the survey were sent in
July of 2017. Reminders were sent after 4 and 8weeks (only to gy-
naecologists who had not responded) and the system was closed after
12 weeks. Once the questionnaire was completed, it was closed and
could not be accessed again. All answers were stored in the survey
system automatically, and after exporting, the data were analysed with
SPSS (IBM Corp. Released 2013. IBM SPSS Statistics for Windows,
Version 22.0. Armonk, NY: IBM Corp.).
3. Results
The survey was started by 48 gynaecologists and completed by 45.
Only the completed questionnaires were included. Of these 45 re-
sponders, 22 were a gynaecologic oncologist (48.9%), 22 were a semi-
specialized or general gynaecologist (48.9%) and one was a fellow in
gynaecologic oncology (2.2%). So, over one third (37.7.3%) of the
gynaecologic oncologists responded to the questionnaire. Table 1 shows
the respondents' baseline characteristics. Six respondents did not per-
form surgical procedures (anymore). Their questionnaire was com-
pleted after the fourth question (because further questions were not
applicable to them), and only the remaining respondents (n=39) were
included in further analyses.
In cases of unambiguous sBOT and mBOT frozen section diagnoses,
about half of the respondents (n=16, 41.0%) would not collect ab-
dominal (rinsing) ﬂuid for cytology, neither perform an infracolic
omentectomy or omental biopsy, nor collect multiple peritoneal biop-
sies (no staging procedure). Two gynaecologists (5.1%) would only
collect abdominal (rinsing) ﬂuid for cytology with respect to both his-
tological types, and one collects abdominal (rinsing) ﬂuid for cytology
and collects a biopsy of the omentum in case of an unambiguous sBOT
frozen section diagnosis. In case of mBOTs, an appendectomy was
considered a standard procedure within the staging procedure by two
thirds of the respondents, and the remaining respondents would only
remove the appendix when the macroscopic appearance is abnormal.
In case of ambiguous sBOT frozen section diagnoses, the number of
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respondents who would perform a staging procedure substantially in-
creased (from 51.3% to 87.2%), and the majority (56.4%) also would
include a lymph node sampling as part of the staging procedure. In
addition, in case of an ambiguous mBOT frozen section diagnosis the
majority of respondents would perform a staging procedure (87.2%),
but a minority (30.8%) would a include lymph node sampling as part of
the staging procedure (see Table 2). A relaparotomy or relaparoscopy to
complete the staging procedure with a lymph node sampling, in case of
a deﬁnite diagnosis of an assumed FIGO stage I invasive carcinoma
(e.g., discordant frozen section diagnosis), would be performed by all
but one respondent in case of a serous tumour (97.4%) and by almost
half of the respondents in case of a mucinous tumour (48.7%). With
respect to lymph node sampling in case of both serous and mucinous
tumours, the majority of respondents would perform a bilateral pelvic
and high para-aortic/paracaval lymph node sampling and prefers re-
moval of at least 10 lymph nodes (see Table 3).
Follow-up visitations of patients with a FIGO stage I BOT are con-
sidered unnecessary by more than half of the respondents with respect
to both serous and mucinous tumours. Some gynaecologists would only
oﬀer follow-up according to patient preference, and a small number
would oﬀer follow-up at their own initiative (see Table 4). With respect
to extra-ovarian disease, all gynaecologists oﬀer follow-up visitations in
case of invasive implants/extra-ovarian LGCS and almost half of them
would already oﬀer follow-up in case of non-invasive implants. Re-
garding follow-up of FIGO stage I sBOTs (n=14), almost half of the
respondents would oﬀer follow-up visitations according to a schedule
that is common in case of epithelial ovarian carcinoma. The remaining
respondents apply a diﬀerent follow-up scheme, for instance follow-up
visitations every six months (n=5) or yearly (n=2), where some in-
dicate that this usually is not as long as is common for ovarian carci-
noma (e.g., 2 years). The applied follow-up schedules in case of mBOTs
(n=12) are comparable to those in case of sBOTs (see Table 4). The
majority of respondents consider anamnesis, transvaginal/−abdominal
ultrasound and gynaecologic examination (vaginal examination with or
without speculum) as standard procedures during follow-up visitations
of patients with a BOT. Approximately half of the respondents routinely
checks serum Ca-125 levels.
Table 1
Respondents' baseline characteristics.
What is your gender? n (%)
• Male 24 (53.3)• Female 21 (46.7)
How long are you working as a gynaecologist? Mean ± SD
• Overall 16.2 ± 8.8• Male 19.9 ± 8.8• Female 12.1 ± 6.9
What is your professional function? n (%)
• Gynaecologist with semi-specialization in gynaecologic
oncology.
22 (48.9)
• Gynaecologic oncologist. 22 (48.9)• Fellow gynaecologic oncology. 1 (2.2)
How many hours do you spend on gynaecologic oncologic
surgery, including surgery with frozen section analysis,
each week?
n (%)
• I do not participate in surgical procedures anymore, or it only
concerns surgical procedures other than ovarian surgery (with
frozen section analysis).
6 (13.3)
• 0–5 13 (28.9)• 5–10 13 (28.9)• 10–15 9 (20.0)• 15–20 3 (6.7)• ≥20 1 (2.2)
How many patients do you diagnose with a BOT each year
(n=39)?
n (%)
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4. Discussion
In daily practice, several factors, such as the limited consequences of
staging procedures in BOTs, diﬀerences in clinicopathological beha-
viour between the histological types, the possibility of discordance
between frozen section and deﬁnite diagnosis and an ambiguous peri-
operative frozen section diagnosis may lead to diﬀerences between
gynaecologists' treatment and follow-up strategies, which may ulti-
mately lead to over- and undertreatment. To be able to minimize this
possible over- and undertreatment, it was considered useful to gain
more knowledge about current practice and opinions regarding treat-
ment and follow-up strategies pertaining to BOTs. The current ques-
tionnaire-based study is the ﬁrst to provide insight into the Dutch gy-
naecologists' surgical strategy related to BOTs based on frozen section
diagnoses. Furthermore, the questionnaire mapped whether the re-
spondents oﬀer follow-up visits to their patients and if so, what diag-
nostic tools are used to screen for a recurrence.
In case of a straightforward sBOT and mBOT frozen section diag-
nosis, approximately half of the respondents would perform a staging
procedure, which is signiﬁcantly less than the 97% reported by Menzin
et al. (2000). This may be explained by the fact that later research has
shown that upstaging may predict a worse prognosis, but does not have
any inﬂuence on further treatment strategies and survival rates (Morice
et al., 2003; Trope et al., 1993; Fauvet et al., 2004; Camatte et al., 2004;
Menzin et al., 2000; Kristensen et al., 2014; Vasconcelos et al., 2015a;
Vasconcelos et al., 2015b). When the results of frozen section analyses
are not straightforward and might tend towards the diagnosis of serous
invasive carcinoma, the number of respondents that would perform a
complete staging procedure substantially increased, and more than half
of the respondents would even perform a staging procedure as re-
commended in case of invasive ovarian carcinoma, which includes a
lymph node sampling. Apparently, those respondents assume that the
risk for an invasive carcinoma and the subsequent need for a second
procedure (no lymph node sampling during initial surgery) outweighs
the chance for overtreatment (unnecessary lymph node sampling
during the ﬁrst procedure) in cases where BOT is the deﬁnite diagnosis.
A contributing factor to this strategy may be the aforementioned
probability of discordance between the frozen section analysis (BOT)
and deﬁnite diagnosis (invasive carcinoma) in 10–17% of the patients
(Pongsuvareeyakul et al., 2012; Bozdag et al., 2016; Ayhan et al.,
2016). In addition, in case of an ambiguous frozen section diagnosis,
tending towards the diagnosis of mucinous invasive carcinoma, the
Table 3
Anatomical sites of lymph node sampling and the preferred number of removed lymph nodes in case of a serous or mucinous ovarian tumour with a questionable
perioperative BOT frozen section diagnosis or in case of a relaparatomy or relaparoscopy after diagnosis of invasive carcinoma with a standard BOT staging procedure
during initial surgery.
Serous tumour Mucinous tumour
Questionable BOT frozen
section diagnosis (n=22)
Second surgery after diagnosis
of invasive carcinoma (n=38)
Questionable BOT frozen
section diagnosis (n= 12)
Second surgery after diagnosis of
invasive carcinoma (n=19)
At which locations do you perform
the lymph node sampling?
n (%) n (%) n (%) n (%)
• Ipsilateral in the pelvic region. 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0)• Bilateral in the pelvic region. 1 (4.5) 1 (2.6) 1 (8.3) 2 (10.5)• Ipsilateral in the pelvic region and
high para-aortic/paracaval.
3 (13.6) 5 (13.2) 2 (16.7) 1 (5.3)
• Bilateral in the pelvic region and
high para-aortic/paracaval.
18 (81.8) 32 (84.2) 8 (66.7) 16 (84.2)
• Only high para-aortic/paracaval. 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
What is the preferred number of
removed lymph nodes?
n (%) n (%) n (%) n (%)
• No minimum number. 4 (18.2) 4 (10.5) 2 (16.7) 2 (10.5)• 10 16 (72.7) 28 (73.7) 9 (75.0) 16 (84.2)• 20 2 (9.1) 6 (15.8) 1 (8.3) 1 (5.3)
Table 4
Respondents' follow-up strategies in case of BOTs.
Serous Mucinous
Follow-up of a FIGO stage I BOT is considered unnecessary by the Dutch guideline. Do you agree (n=39)? n (%) n (%)
• Yes, I will not oﬀer follow-up visitations (except one postoperative check). 25 (64.1) 27 (69.2)• Yes, I will not oﬀer follow-up unless the patients prefers this. 9 (23.1) 8 (20.5)• No, I will oﬀer follow-up on my own initiative. 5 (12.8) 4 (10.3)
Which follow-up schedule would you apply in case you would oﬀer follow-up in patients with a FIGO stage I sBOT (n=14) or mBOT
(n=12)?
n (%) n (%)
• A follow-up schedule as is common for epithelial ovarian carcinoma. 6 (42.9) 4 (33.3)• Otherwise, … 8 (57.1) 8 (66.7)
In case you would not oﬀer follow-up visitation in case of a FIGO stage I BOT, would you do this in case of extra-ovarian disease in the
omentum or other peritoneal surfaces (n=39)?
n (%) n (%)
• Not applicable, I would oﬀer follow-up visitations anyway. 4 (10.3) Not applicable• Yes, in that case I would oﬀer follow-up visitations. 17 (43.6)• Yes, but only but only if it concerns invasive implants. 18 (46.2)• No, I would still not oﬀer follow-up visitations. 0 (0)
During a follow-up visitation of an sBOT (n=14) or mBOT (n=12) I consider the following procedures as standard: n (%) n (%)
• Anamnesis 14 (100) 12 (100)• Transvaginal/−abdominal ultrasound 13 (92.9) 11 (91.7)• Gynaecologic examination (vaginal examination with or without speculum) 10 (71.4) 9 (75)• Serum Ca-125 levels 8 (57.1) 5 (41.7)• Additional imaging studies 1 (7.1) 0 (0)• Cytological examination of the vaginal vault 0 (0) 0 (0)
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number of respondents that would perform a complete BOT staging
procedure substantially increases. However, in contrast to serous tu-
mours, only a minority would include a lymph node sampling as part of
the staging procedure (30.8% versus 56.4%). The same is true for the
number of respondents that would perform a relaparotomy or laparo-
scopy to complete the surgical staging with a lymph node sampling in
case of patients in whom a BOT frozen section result was changed to an
invasive carcinoma (48.7% and 97.4% in mucinous and serous tu-
mours, respectively). The more aggressive strategy in case of serous
ovarian tumours is most likely because of the fact that serous ovarian
carcinomas have a signiﬁcantly higher chance of occult lymph node
metastases and because adjuvant chemotherapy is more beneﬁcial
when compared to mucinous ovarian carcinomas (Kleppe et al., 2011;
Ayhan et al., 2005; Schmeler et al., 2010; Prat, 2012a; Prat, 2012b;
Ricci et al., 2018).
Despite the fact that bilateral pelvic, and high para-aortic/paracaval
lymph node sampling is recommended, some respondents (+/− 20%)
indicated that they would perform a less extensive sampling [only
(ipsilateral) pelvic lymph node sampling or ipsilateral pelvic with high
para-aortic/paracaval sampling], without major diﬀerences with re-
spect to both histological subtypes (Pereira et al., 2007; Cass et al.,
2001; UpToDate: Cancer of the ovary, fallopian tube, and peritoneum:
Staging and initial surgical management, n.d.). Concerning the minimum
number of removed lymph nodes, the majority of respondents prefer
removal of at least 10 lymph nodes, which is also recommended by the
Dutch guideline and some previous reports (Chan et al., 2007; Carnino
et al., 1997). However, some of the respondents advocate removal of at
least 20 lymph nodes, probably because the 5-year survival rate seems
to improve in those cases (Kleppe et al., 2016).
With regard to follow-up of BOTs in case of a bilateral salpingo-
oophorectomy (BSO), approximately two thirds of the respondents re-
port that follow-up visits in those cases (without extra-ovarian disease)
are irrational because of the high disease free and overall survival rates
of BOTs (Trimble et al., 2002; Karlsen et al., 2016). In contrast, all of
the respondents oﬀer follow-up visits in case of invasive extra-ovarian
disease. However, the respondents oﬀering follow-up apply diﬀerent
schedules with respect to the frequency and duration of follow-up.
Some respondents advocate applying ovarian cancer post-treatment
surveillance guidelines to patients with BOTs (with or without extra-
ovarian disease), which is not in agreement with the Dutch guideline
but which is recommended by others (UpToDate: Borderline ovarian tu-
mors, n.d.; Cadron et al., 2007; Zanetta et al., 2001a). With respect to
the procedures performed during follow-up visits regarding BOTs after
a BSO, the majority of respondents would perform a clinical examina-
tion and vaginal ultrasound examination (Zanetta et al., 2001b; Testa
et al., 2012; Fischerova, 2011). Furthermore, approximately half of the
respondents determines serum Ca-125 levels, which is recommended by
some authors. However, serum Ca-125 are less often elevated in case of
sBOTs, when compared to serous carcinomas, and they are rarely ele-
vated in mBOTs (Cadron et al., 2007; Zanetta et al., 2001b; Fischerova
et al., 2012; Messalli et al., 2013).
Our study has several limitations. First of all, the questionnaire was
designed and tested only by the author panel. There was no validation
of the survey by a pilot study because of the small size of the target
population, which made it impossible to adjust and improve the content
of the questionnaire after initial testing. However, it is questionable
whether these limitations aﬀected the outcomes. Another limitation of
this study was the moderate response rate. To reach out to gynaecol-
ogists involved in ovarian surgery with perioperative frozen section
analysis, the questionnaire was sent to a large group of potential re-
spondents (all gynaecologist members of the Dutch Working Party on
Oncologic Gynaecology). It is known that invitations to such ques-
tionnaires are frequently declined because of a lack of time, interest or
knowledge. Nevertheless, over one third of the gynaecologic oncolo-
gists who should perform or supervise all ovarian surgery with frozen
section analysis completed the survey, which is suﬃcient to gain insight
into the current daily practice with respect to BOTs. On the other hand,
gynaecologic oncologists, who are involved in all procedures, might
have biased the answers of the remaining respondents (semi-specialized
gynaecologists or fellow gynaecologic oncology).
In conclusion, it can be stated that diﬀerent treatment strategies are
applied by the Dutch gynaecologists involved in ovarian surgery with
perioperative frozen section analysis. It should be noted that approxi-
mately half of the gynaecologists do not perform a staging procedure in
case of BOTs, while the number decreases in case of an ambiguous
frozen section result. Furthermore, a considerable number of gynae-
cologists would perform a staging procedure including a lymph node
sampling in case of an ambiguous BOT frozen section diagnosis, espe-
cially in case of serous tumours. In addition, nearly all gynaecologists
would perform a relaparotomy or laparoscopy to perform a lymph node
sampling in case of a presumed FIGO stage I serous invasive carcinoma
after a BOT frozen section diagnosis, which applies to only half of the
gynaecologists in case of a mucinous carcinoma. Lymph node sampling
is performed in the recommended regions by the majority of gynae-
cologists, but some prefer a less extensive sampling, which is also true
for the minimum number of removed lymph nodes. Last but not least,
the follow-up strategy varies considerably amongst gynaecologists,
especially with respect to the duration and frequency of follow-up and
also with regard to what diagnostic tools are used. Future studies
should focus on whether the aforementioned diﬀerences with respect to
treatment and follow-up policies regarding BOTs have any con-
sequences for patient outcomes.
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